EPFL

Brain Computer Interface (BCI) Enables Thought-Controlled Walking after Spinal Cord Injury

Retrieved on: 
Wednesday, May 24, 2023
Medical device, Spinal cord stimulator, BCI, ARC, Movement, CHUV, Paralysis, CEA-Leti: Laboratoire d'électronique des technologies de l'information, Euronext, Research, EPFL, SCI, Safety, Lausanne University Hospital, Nature

EINDHOVEN, the Netherlands, May 24, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces a publication in Nature showing that a wireless brain-computer interface (BCI) can use thought to modulate ARC Therapy.

Key Points: 
  • EINDHOVEN, the Netherlands, May 24, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces a publication in Nature showing that a wireless brain-computer interface (BCI) can use thought to modulate ARC Therapy.
  • Researchers reported that when paired with ARC Therapy, an implanted BCI allowed an individual to gain augmented control over when and how he moved his paralyzed legs.
  • “I look forward to working with the ONWARD team to advance this important new technology.”
    The data published today are part of an ongoing clinical feasibility study investigating the safety and preliminary effectiveness of brain-controlled spinal cord stimulation after SCI.
  • All ONWARD devices and therapies, including but not limited to ARC-IM, ARC-EX, and ARC Therapy, are investigational and not available for commercial use.

ONWARD Announces First-in-Human Use of ARC-IM™ Lead to Restore Movement and Function after Spinal Cord Injury

Retrieved on: 
Monday, May 15, 2023
Blood pressure, Lead, Swiss, IPG, University, University of Calgary, Lausanne, Spinal cord, ARC, Quality of life, Research, CHUV, Movement, Euronext, Patient, EPFL, SCI, FDA, Swiss Federal Institute of Aquatic Science and Technology, Pharmaceutical industry, Medical device, Nature, MD

EINDHOVEN, the Netherlands, May 15, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced the successful first-in-human use of its investigational ARC-IM Lead.

Key Points: 
  • EINDHOVEN, the Netherlands, May 15, 2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announced the successful first-in-human use of its investigational ARC-IM Lead.
  • The ARC-IM Lead delivers targeted electrical pulses to the spinal cord and is a key component of the ONWARD ARC-IM system, an innovative platform engineered to deliver ARC Therapy to address multiple indications.
  • The ARC-IM Lead is designed to be used with the ARC-IM neurostimulator (IPG) and is purpose-built for placement along the spinal cord to stimulate the dorsal roots, with specific parameters designed for each anatomical location.
  • “The purpose-designed ARC-IM Lead will unlock our ability to optimally deliver ARC Therapy to address many of the challenges faced by people with spinal cord injury,” said Dave Marver, CEO of ONWARD.

BioInnovation Institute & Science Prize for Innovation winners announced

Retrieved on: 
Thursday, April 13, 2023
Blood pressure, Memorial Sloan Kettering Cancer Center, Prize, Swiss Federal Institute of Technology, Honey, Chromosome, University, Tetraplegia, Neuroprosthetics, Breeding, Spinal cord, Cancer, Polymer, MSKCC, Innovation, Research, MIT, University of North Carolina at Greensboro, USD, Associate, Paralysis, Entrepreneurship, Seumas McNally Grand Prize, EPFL, BII, Swiss Federal Institute of Aquatic Science and Technology, SCI, Pharmaceutical industry, Science

The annual award hosted by BioInnovation Institute and Science aims to recognize and celebrate bold researchers who are asking fundamental questions at the intersection of life sciences and entrepreneurship.

Key Points: 
  • The annual award hosted by BioInnovation Institute and Science aims to recognize and celebrate bold researchers who are asking fundamental questions at the intersection of life sciences and entrepreneurship.
  • The three winners will have their essays published in the journal, Science, and will be invited into BII's entrepreneurial ecosystem.
  • In addition, the Grand Prize winner will receive USD 25,000 and each finalist will receive USD 10,000 at a grand award ceremony in Copenhagen, Denmark, April 27th.
  • The BII & Science Prize for Innovation is in its second year, with applications received from around the world.

BioInnovation Institute & Science Prize for Innovation winners announced

Retrieved on: 
Thursday, April 13, 2023
Blood pressure, Memorial Sloan Kettering Cancer Center, Prize, Swiss Federal Institute of Technology, Honey, Chromosome, University, Tetraplegia, Neuroprosthetics, Breeding, Spinal cord, Cancer, Polymer, MSKCC, Innovation, Research, MIT, University of North Carolina at Greensboro, USD, Associate, Paralysis, Entrepreneurship, Seumas McNally Grand Prize, EPFL, BII, Swiss Federal Institute of Aquatic Science and Technology, SCI, Pharmaceutical industry, Science

The annual award hosted by BioInnovation Institute and Science aims to recognize and celebrate bold researchers who are asking fundamental questions at the intersection of life sciences and entrepreneurship.

Key Points: 
  • The annual award hosted by BioInnovation Institute and Science aims to recognize and celebrate bold researchers who are asking fundamental questions at the intersection of life sciences and entrepreneurship.
  • The three winners will have their essays published in the journal, Science, and will be invited into BII's entrepreneurial ecosystem.
  • In addition, the Grand Prize winner will receive USD 25,000 and each finalist will receive USD 10,000 at a grand award ceremony in Copenhagen, Denmark, April 27th.
  • The BII & Science Prize for Innovation is in its second year, with applications received from around the world.

Archer Materials advances to wafer-scale quantum device fabrication

Retrieved on: 
Thursday, April 6, 2023
Vacuum, AXE, Temperature, HEMT, QED vacuum, Engineering, CMOS, TSMC, Architecture, EPFL, Environment, Semiconductor, Microscope, Electronics, Video game, Archery

SYDNEY, Australia, April 05, 2023 (GLOBE NEWSWIRE) -- Archer Materials Limited (“Archer”, the “Company”, “ASX: AXE”) is pleased to provide shareholders an update on the progress of its 12CQ chip development. During the past months the Company’s progress has involved the following:

Key Points: 
  • 12CQ chip development advances to wafer-scale quantum electronic device fabrication using foundry-compatible UV optical and E-beam lithography.
  • Hundreds of quantum electronic devices and qubit materials prepared for testing, measurement, integration, and optimisation towards qubit control and readout.
  • Archer has now secured access to a local state-of-the-art cryogenic quantum device measurement laboratory and commenced technical programs of low-temperature (cryogenic) characterisation of QEDs.
  • An Archer 4 x 4 mm single-chip quantum electronic device after installing and bonding into a commercial chip carrier.

SmarDex Revolutionizes DeFi Landscape, Becomes Fastest Growing Ethereum Protocol with $30M TVL in 14 Days

Retrieved on: 
Monday, April 3, 2023
Ethereum, FTX, Decentralized finance, Movement, Disaster, Traction, TVL, Growth, EPFL, Ecosystem, Cryptocurrency

Their innovative approach to transforming Impermanent Loss into Impermanent Gain has attracted more than $30 million in total value locked (TVL) within just two weeks, making it the fastest-growing protocol on the Ethereum network.

Key Points: 
  • Their innovative approach to transforming Impermanent Loss into Impermanent Gain has attracted more than $30 million in total value locked (TVL) within just two weeks, making it the fastest-growing protocol on the Ethereum network.
  • Long considered a substantial barrier to entry for liquidity providers, Impermanent Loss has impeded the growth of the DeFi movement.
  • The Swiss researchers' discovery offers a novel way to tackle this challenge, potentially leading to a more secure, transparent, and inclusive financial system.
  • Consequently, SmarDex, the team behind smardex.io, has managed to address a significant obstacle for liquidity providers, unlocking new possibilities for the DeFi sector.

Gain Therapeutics Announces Grant Award by Eurostars with Innosuisse for Alpha-1 Antitrypsin Deficiency Research Program

Retrieved on: 
Tuesday, March 21, 2023
University of Helsinki, DSM-IV codes, University, Hepatology, Protein folding, Research, CNS, Lung, Institute for Research in Biomedicine, A1AT, GM, IRB, Quality control, Drug discovery, Liver, AAT, EPFL, Therapy, Eurostar International Limited, Safety, Pharmaceutical industry, Medical device

This grant supports a research project to develop novel small molecule allosteric regulators against Alpha-1 Antitrypsin (AAT) Deficiency, a rare genetic condition that can result in serious lung and liver diseases.

Key Points: 
  • This grant supports a research project to develop novel small molecule allosteric regulators against Alpha-1 Antitrypsin (AAT) Deficiency, a rare genetic condition that can result in serious lung and liver diseases.
  • “We are pleased that Eurostars and Innosuisse recognize that Gain Therapeutics’ allosteric small molecule regulators provide a new approach to address AAT deficiency-related metabolic diseases.
  • We look forward to advancing our AAT program with this consortium, which combines our unique targeting approach with novel in vitro and in vivo models.
  • Consequently, these models will be used as a disease model where lead small molecules therapeutic power can be tested in a physiological setting.”

Is there a programming language for the brain? Dandelion Science Corp and the Swiss Federal Institute of Technology (EPFL) announce brain research collaboration.

Retrieved on: 
Tuesday, February 28, 2023
Merck, Taraxacum, Neurochemistry, Psychiatry, Drug development, EPFL, Partnership, Brain, Research, Publication, Neurology, Google Images, Dimitri Van De Ville, Science, DSM-IV codes, Novartis, Language, Health, Medical imaging, Biogen

NEW YORK, Feb. 28, 2023 /PRNewswire/ -- Dandelion Science Corp, a US-Swiss neurotechnology company, is excited to announce a new neuroscience research collaboration with Professor Dimitri Van De Ville at EPFL in Switzerland. This collaboration will advance Dandelion's technology platform with the latest in neuroimaging systems.

Key Points: 
  • NEW YORK, Feb. 28, 2023 /PRNewswire/ -- Dandelion Science Corp, a US-Swiss neurotechnology company, is excited to announce a new neuroscience research collaboration with Professor Dimitri Van De Ville at EPFL in Switzerland.
  • At Dandelion, we are developing a platform to program network dynamics in the brain.
  • "With this partnership, we will combine state-of-the-art imaging technology with the latest neuroscientific insights to probe brain function and dysfunction.
  • "Technology is starting to offer solutions to neuroscience research that a few years ago were out of our reach.

Rapid Silicon Announces $30M Series A Round

Retrieved on: 
Monday, January 9, 2023
Electronic Design Automation, Semiconductor, Technology, Software, Artificial Intelligence, Hardware, Benchmark, Field-programmable gate array, EPFL, Raptor, Silicon, AI, PLD, Workflow, EDA, Renewable energy, Cryptocurrency, FPGA

Rapid Silicon, a provider of AI and intelligent edge-focused FPGAs based on open-source technology, today announced its $30M Series A Round.

Key Points: 
  • Rapid Silicon, a provider of AI and intelligent edge-focused FPGAs based on open-source technology, today announced its $30M Series A Round.
  • The company has closed $15M in funding from Cambium Capital and others, including all existing investors from its seed round.
  • Rapid Silicon’s software, Raptor Design Suite, is the world’s first commercial FPGA EDA suite based on end-to-end open-source software.
  • “With open-source software, Rapid Silicon is removing the barriers and providing its customers with a robust end-to-end FPGA design workflow.

ONWARD Awarded European Innovation Council Grant to Further Develop Brain-Computer Interface Technology; Company also Wins First Place in 2022 Brain-Computer Interface Awards

Retrieved on: 
Monday, November 21, 2022
Medical Devices, Health, Other Health, Research, Science, Biotechnology, University of California, San Francisco, EUR, CHUV, Euronext, Partnership, Materials Research Science and Engineering Centers, In the First Place, International, SCI, Interface (computing), Stanford University, Swiss Federal Institute of Aquatic Science and Technology, Loss of Sensation, Science, EIC, Quality of life, Spinal cord injury, Hyperreflexia, U.S. FDA, Pathfinder, EPFL, Swiss Federal Institute of Technology, Research, Spinal cord, Paralysis, Nature, Incontinence, Paraplegia, ARC, Record, European Innovation Council, Tetraplegia, Lausanne University Hospital, University, BCI, Movement, Infection, Hope, Health, NEMO, Brain–computer interface, Medical device, Pharmaceutical industry

Separately, ONWARD announced that it was the First Place Winner of the 2022 Brain-Computer Interface (BCI) Award .

Key Points: 
  • Separately, ONWARD announced that it was the First Place Winner of the 2022 Brain-Computer Interface (BCI) Award .
  • The award was granted to ONWARD and several research partners for their submission, Walking naturally after spinal cord injury using a brain-spine interface.
  • ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injuries.
  • You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.